Vignesh Raghunath, MD
Hospitalist · Morristown, NJNPI 1639580475
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,081 of the $3,697 with a category attached, or 83.3%. It is spread thinly across 25 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,359, more than ten times the $35 reported in 2020. Among hospitalist clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 184 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$516
- Pfizer$407
- Abbott$383
- Novartis$359
- GSK$353
- Amgen$280
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,08183%
- Education$60116%
- Entertainment$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $516 |
| Pfizer | 26 | $407 |
| Abbott | 5 | $383 |
| Novartis | 18 | $359 |
| GSK | 32 | $353 |
| Amgen | 17 | $280 |
| AstraZeneca | 13 | $193 |
| Astellas Pharma US Inc | 2 | $190 |
| Boehringer Ingelheim | 11 | $172 |
| E.r. Squibb & Sons, L.L.C. | 10 | $150 |
| Novo Nordisk | 8 | $148 |
| Optinose US, Inc. | 5 | $102 |
| Baxter Healthcare | 4 | $89 |
| Abiomed | 2 | $59 |
| Merck | 3 | $49 |
| Lilly USA, LLC | 3 | $46 |
| Chiesi USA, Inc. | 2 | $39 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $32 |
| Bayer | 2 | $26 |
| Edwards Lifesciences | 1 | $21 |
| Impulse Dynamics (USA) Inc. | 1 | $21 |
| Harmony Biosciences LLC | 1 | $16 |
| Opsens Inc. | 1 | $15 |
| United Therapeutics Corporation | 1 | $15 |
| Medivance, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,697 in reported general payments places this provider in the 95th percentile of 567 hospitalist providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 77 | $93,987 |
| XareltoRivaroxaban | 35 | $41,446 |
| EntrestoSacubitril/Valsartan | 20 | $31,888 |
| BrilintaTicagrelor | 12 | $10,418 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 15 | $3,067 |
| Metoprolol Succinate | 132 | $2,099 |
| Rosuvastatin Calcium | 123 | $1,509 |
| Atorvastatin Calcium | 117 | $1,499 |
| Ezetimibe | 44 | $1,225 |
| Valsartan | 36 | $822 |
| Torsemide | 32 | $768 |
| Amlodipine Besylate | 92 | $631 |
| ClopidogrelClopidogrel Bisulfate | 37 | $541 |
| Carvedilol | 33 | $457 |
| Olmesartan Medoxomil | 38 | $397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $407 | $93,98777 claims |
| NovartisEntresto | $359 | $31,88820 claims |
| AstraZenecaBrilinta | $193 | $10,41812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 567 hospitalist providers in New Jersey.
Other hospitalist in Morristown
- Jhonsua Jimenez AriasMorristown$15K
- Ahmed HassaninMorristown$15K
- Rebecca ZweiflerMorristown$6K
- Zainab MirzaMorristown$6K
- Brian BaksaMorristown$4K
- Peter RoytmanMorristown$3K
- Nivedita AllaMorristown$2K
- Christine GergesMorristown$2K
- Anamika SharmaMorristown$1K
- Shashi RajaMorristown$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.